Compounds > 4,4'-thiodianiline

Page last updated: 2024-12-05

4,4'-thiodianiline

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

4,4'-Thiodianiline (TDA) is an organic compound with the formula (H2NC6H4)2S. It is a white solid. TDA is a precursor to the production of the rubber accelerator 4,4'-dithiodimorpholine and the pesticide 4,4'-dichlorodiphenylsulfone. The compound is prepared by the reaction of aniline with sulfur monochloride. TDA is a suspected human carcinogen and is associated with respiratory and skin irritation. TDA is studied for its potential use in the synthesis of new materials with specific properties, such as conductivity and mechanical strength. It is also studied for its environmental impact and its potential role in the development of new environmental remediation technologies.'

4,4'-thiodianiline: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	8765
CHEMBL ID	348856
CHEBI ID	82374
SCHEMBL ID	49068
MeSH ID	M0058279

Synonyms (107)

Synonym
EU-0033395
HMS1473I11
AC-16457
BB 0261090
wln: zr dsr dz
nci-c01707
4,4'-thiobis[aniline]
4,4'-diaminophenyl sulfide
nsc6191
nsc-6191
sulfide, bis(p-aminophenyl)
thiodi-p-phenylenediamine
benzenamine,4'-thiobis-
aniline,4'-thiodi-
thioaniline
bis(p-aminophenyl) sulfide
4,4'-thiodianiline
bis(4-aminophenyl) sulfide
p,p'-diaminodiphenyl sulfide
4,4'-diaminodiphenyl sulfide
di(p-aminophenyl) sulfide
p,p-thiodianiline
4,4'-thiobisbenzenamine
139-65-1
4,4'-thioaniline
benzenamine, 4,4'-thiobis-
aniline, 4,4'-thiodi-
4,4'-sulfanediyldianiline
4-(4-aminophenyl)sulfanylaniline
p,p'-thiodianiline
IDI1_019505
4,4'-diamino diphenyl sulfide
CHEMDIV3_000187
NCGC00091380-01
bis(4-aminophenyl)sulphide
sulfide, diphenyl, 4,4'-diamino-
4,4'-thiobis(aniline)
einecs 205-370-9
brn 1875513
p,p'-diaminodiphenyl sulphide
bis(4-aminophenyl)sulfide
para,para'-diaminodiphenyl sulphide
bis(para-aminophenyl)sulphide
para,para'-thiodianiline
4,4'-diaminodiphenylsulfide
4,4'-diaminodiphenylsulphide
di(p-aminophenyl)sulphide
thiodi-para-phenylenediamine
bis(p-aminophenyl)sulphide
ccris 585
bis(p-aminophenyl)sulfide
4,4-diaminodiphenyl sulphide
hsdb 5074
ai3-52492
di(para-aminophenyl) sulphide
nsc 6191
4,4'-diaminodiphenyl sulfide, 98%
NCGC00091380-02
NCGC00091380-03
STK502135
inchi=1/c12h12n2s/c13-9-1-5-11(6-2-9)15-12-7-3-10(14)4-8-12/h1-8h,13-14h2
icnfhjvpajkphw-uhfffaoysa-
BRD-K54288638-001-01-9
chebi:82374 ,
3-[(4-aminophenyl)thio]aniline
CHEMBL348856
smr001252212
MLS002303004
4-aminophenyl sulfide
AKOS000120259
A807574
4,4-thiodianiline
NCGC00091380-05
NCGC00091380-04
6ggu990bqf ,
unii-6ggu990bqf
C19303
HMS3091M14
dtxsid9021344 ,
dtxcid501344
cas-139-65-1
tox21_400005
4-[(4-aminophenyl)sulfanyl]aniline
FT-0617024
4,4'-thiodianiline [iarc]
4,4'-thiodianiline [hsdb]
SCHEMBL49068
4-[(4-aminophenyl)thio]aniline
4-aminophenylsulfide
4-[(4-aminophenyl)sulfanyl]phenylamine #
J-514036
sr-01000389036
SR-01000389036-1
mfcd00025342
4,4'-diaminodiphenyl sulfide, analytical standard
EN300-16804
4-aminophenylthioether
4-aminophenylthioether 10 microg/ml in acetonitrile
J-007300
AS-14556
4,4/'-thiodianiline
Q10859491
H11872
4,4'-thio-dianiline
CS-W014838
SY055354
4,4 inverted exclamation mark -thiodianiline

Research Excerpts

Bioavailability

Excerpt	Reference	Relevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

Class	Description
substituted aniline
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (56)

Potency Measurements

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, JmjC domain-containing histone demethylation protein 3A	Homo sapiens (human)	Potency	31.6228	0.6310	35.7641	100.0000	AID504339
Luciferase	Photinus pyralis (common eastern firefly)	Potency	47.2724	0.0072	15.7588	89.3584	AID1224835; AID624030
RAR-related orphan receptor gamma	Mus musculus (house mouse)	Potency	14.2326	0.0060	38.0041	19,952.5996	AID1159521; AID1159523
GALC protein	Homo sapiens (human)	Potency	1.5849	28.1838	28.1838	28.1838	AID1159614
GLS protein	Homo sapiens (human)	Potency	50.1187	0.3548	7.9355	39.8107	AID624170
TDP1 protein	Homo sapiens (human)	Potency	13.0132	0.0008	11.3822	44.6684	AID686978; AID686979
GLI family zinc finger 3	Homo sapiens (human)	Potency	49.6137	0.0007	14.5928	83.7951	AID1259368; AID1259369
AR protein	Homo sapiens (human)	Potency	35.6616	0.0002	21.2231	8,912.5098	AID1259243; AID1259381; AID743036; AID743042
thyroid stimulating hormone receptor	Homo sapiens (human)	Potency	1.0000	0.0013	18.0743	39.8107	AID926; AID938
estrogen receptor 2 (ER beta)	Homo sapiens (human)	Potency	37.9319	0.0006	57.9133	22,387.1992	AID1259377; AID1259378
nuclear receptor subfamily 1, group I, member 3	Homo sapiens (human)	Potency	31.9920	0.0010	22.6508	76.6163	AID1224838; AID1224839; AID1224893
progesterone receptor	Homo sapiens (human)	Potency	30.3775	0.0004	17.9460	75.1148	AID1346784; AID1346795
cytochrome P450 family 3 subfamily A polypeptide 4	Homo sapiens (human)	Potency	5.0250	0.0123	7.9835	43.2770	AID1645841
glucocorticoid receptor [Homo sapiens]	Homo sapiens (human)	Potency	13.7986	0.0002	14.3764	60.0339	AID720691; AID720692
retinoic acid nuclear receptor alpha variant 1	Homo sapiens (human)	Potency	22.0710	0.0030	41.6115	22,387.1992	AID1159552; AID1159553; AID1159555
retinoid X nuclear receptor alpha	Homo sapiens (human)	Potency	6.9167	0.0008	17.5051	59.3239	AID1159527
estrogen-related nuclear receptor alpha	Homo sapiens (human)	Potency	45.2287	0.0015	30.6073	15,848.9004	AID1224819; AID1224820; AID1224841
farnesoid X nuclear receptor	Homo sapiens (human)	Potency	17.1846	0.3758	27.4851	61.6524	AID588527; AID743217
pregnane X nuclear receptor	Homo sapiens (human)	Potency	31.2800	0.0054	28.0263	1,258.9301	AID1346982; AID720659
estrogen nuclear receptor alpha	Homo sapiens (human)	Potency	14.0415	0.0002	29.3054	16,493.5996	AID1259244; AID588514; AID743069; AID743075; AID743077; AID743079
G	Vesicular stomatitis virus	Potency	0.7098	0.0123	8.9648	39.8107	AID1645842
cytochrome P450 2D6	Homo sapiens (human)	Potency	20.0048	0.0010	8.3798	61.1304	AID1645840
peroxisome proliferator-activated receptor delta	Homo sapiens (human)	Potency	28.6741	0.0010	24.5048	61.6448	AID588534; AID588535; AID743212; AID743215
peroxisome proliferator activated receptor gamma	Homo sapiens (human)	Potency	12.2775	0.0010	19.4141	70.9645	AID743094; AID743191
vitamin D (1,25- dihydroxyvitamin D3) receptor	Homo sapiens (human)	Potency	30.8956	0.0237	23.2282	63.5986	AID743223
aryl hydrocarbon receptor	Homo sapiens (human)	Potency	12.9430	0.0007	23.0674	1,258.9301	AID743085; AID743122
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a	Homo sapiens (human)	Potency	24.3365	0.0017	23.8393	78.1014	AID743083
Histone H2A.x	Cricetulus griseus (Chinese hamster)	Potency	73.1994	0.0391	47.5451	146.8240	AID1224845; AID1224896
thyroid hormone receptor beta isoform 2	Rattus norvegicus (Norway rat)	Potency	7.6959	0.0003	23.4451	159.6830	AID743065
mitogen-activated protein kinase 1	Homo sapiens (human)	Potency	39.8107	0.0398	16.7842	39.8107	AID995
nuclear factor erythroid 2-related factor 2 isoform 1	Homo sapiens (human)	Potency	37.9802	0.0006	27.2152	1,122.0200	AID651741; AID743202; AID743219
cytochrome P450 3A4 isoform 1	Homo sapiens (human)	Potency	12.5893	0.0316	10.2792	39.8107	AID884; AID885
Gamma-aminobutyric acid receptor subunit pi	Rattus norvegicus (Norway rat)	Potency	12.5893	1.0000	12.2248	31.6228	AID885
Voltage-dependent calcium channel gamma-2 subunit	Mus musculus (house mouse)	Potency	12.1972	0.0015	57.7890	15,848.9004	AID1259244
Interferon beta	Homo sapiens (human)	Potency	0.7098	0.0033	9.1582	39.8107	AID1645842
HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)	Potency	0.7098	0.0123	8.9648	39.8107	AID1645842
Gamma-aminobutyric acid receptor subunit beta-1	Rattus norvegicus (Norway rat)	Potency	12.5893	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit delta	Rattus norvegicus (Norway rat)	Potency	12.5893	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit gamma-2	Rattus norvegicus (Norway rat)	Potency	12.5893	1.0000	12.2248	31.6228	AID885
Glutamate receptor 2	Rattus norvegicus (Norway rat)	Potency	12.1972	0.0015	51.7393	15,848.9004	AID1259244
Gamma-aminobutyric acid receptor subunit alpha-5	Rattus norvegicus (Norway rat)	Potency	12.5893	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-3	Rattus norvegicus (Norway rat)	Potency	12.5893	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit gamma-1	Rattus norvegicus (Norway rat)	Potency	12.5893	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-2	Rattus norvegicus (Norway rat)	Potency	12.5893	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-4	Rattus norvegicus (Norway rat)	Potency	12.5893	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit gamma-3	Rattus norvegicus (Norway rat)	Potency	12.5893	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-6	Rattus norvegicus (Norway rat)	Potency	12.5893	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-1	Rattus norvegicus (Norway rat)	Potency	12.5893	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit beta-3	Rattus norvegicus (Norway rat)	Potency	12.5893	1.0000	12.2248	31.6228	AID885
Guanine nucleotide-binding protein G	Homo sapiens (human)	Potency	56.2341	1.9953	25.5327	50.1187	AID624287
Gamma-aminobutyric acid receptor subunit beta-2	Rattus norvegicus (Norway rat)	Potency	12.5893	1.0000	12.2248	31.6228	AID885
GABA theta subunit	Rattus norvegicus (Norway rat)	Potency	12.5893	1.0000	12.2248	31.6228	AID885
Inositol hexakisphosphate kinase 1	Homo sapiens (human)	Potency	0.7098	0.0123	8.9648	39.8107	AID1645842
Gamma-aminobutyric acid receptor subunit epsilon	Rattus norvegicus (Norway rat)	Potency	12.5893	1.0000	12.2248	31.6228	AID885
cytochrome P450 2C9, partial	Homo sapiens (human)	Potency	0.7098	0.0123	8.9648	39.8107	AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
rac GTPase-activating protein 1 isoform a	Homo sapiens (human)	IC50 (µMol)	13.1600	7.3900	57.8904	301.2400	AID624330
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (50)

Process	via Protein(s)	Taxonomy
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell activation involved in immune response	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to virus	Interferon beta	Homo sapiens (human)
positive regulation of autophagy	Interferon beta	Homo sapiens (human)
cytokine-mediated signaling pathway	Interferon beta	Homo sapiens (human)
natural killer cell activation	Interferon beta	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT protein	Interferon beta	Homo sapiens (human)
cellular response to interferon-beta	Interferon beta	Homo sapiens (human)
B cell proliferation	Interferon beta	Homo sapiens (human)
negative regulation of viral genome replication	Interferon beta	Homo sapiens (human)
innate immune response	Interferon beta	Homo sapiens (human)
positive regulation of innate immune response	Interferon beta	Homo sapiens (human)
regulation of MHC class I biosynthetic process	Interferon beta	Homo sapiens (human)
negative regulation of T cell differentiation	Interferon beta	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Interferon beta	Homo sapiens (human)
defense response to virus	Interferon beta	Homo sapiens (human)
type I interferon-mediated signaling pathway	Interferon beta	Homo sapiens (human)
neuron cellular homeostasis	Interferon beta	Homo sapiens (human)
cellular response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
cellular response to virus	Interferon beta	Homo sapiens (human)
negative regulation of Lewy body formation	Interferon beta	Homo sapiens (human)
negative regulation of T-helper 2 cell cytokine production	Interferon beta	Homo sapiens (human)
positive regulation of apoptotic signaling pathway	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell differentiation	Interferon beta	Homo sapiens (human)
natural killer cell activation involved in immune response	Interferon beta	Homo sapiens (human)
adaptive immune response	Interferon beta	Homo sapiens (human)
T cell activation involved in immune response	Interferon beta	Homo sapiens (human)
humoral immune response	Interferon beta	Homo sapiens (human)
positive regulation of T cell mediated cytotoxicity	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
adaptive immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of T cell anergy	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
defense response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
detection of bacterium	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of interleukin-12 production	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of interleukin-6 production	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protection from natural killer cell mediated cytotoxicity	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
innate immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of dendritic cell differentiation	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class Ib	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
negative regulation of inflammatory response to antigenic stimulus	Guanine nucleotide-binding protein G	Homo sapiens (human)
renal water homeostasis	Guanine nucleotide-binding protein G	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Guanine nucleotide-binding protein G	Homo sapiens (human)
regulation of insulin secretion	Guanine nucleotide-binding protein G	Homo sapiens (human)
cellular response to glucagon stimulus	Guanine nucleotide-binding protein G	Homo sapiens (human)
inositol phosphate metabolic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
negative regulation of cold-induced thermogenesis	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol phosphate biosynthetic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (20)

Process	via Protein(s)	Taxonomy
cytokine activity	Interferon beta	Homo sapiens (human)
cytokine receptor binding	Interferon beta	Homo sapiens (human)
type I interferon receptor binding	Interferon beta	Homo sapiens (human)
protein binding	Interferon beta	Homo sapiens (human)
chloramphenicol O-acetyltransferase activity	Interferon beta	Homo sapiens (human)
TAP binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
signaling receptor binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protein binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
peptide antigen binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
TAP binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protein-folding chaperone binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
G protein activity	Guanine nucleotide-binding protein G	Homo sapiens (human)
adenylate cyclase activator activity	Guanine nucleotide-binding protein G	Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol heptakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 5-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
protein binding	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
ATP binding	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 1-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 3-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (22)

Process	via Protein(s)	Taxonomy
extracellular space	Interferon beta	Homo sapiens (human)
extracellular region	Interferon beta	Homo sapiens (human)
Golgi membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
endoplasmic reticulum	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
Golgi apparatus	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
plasma membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
cell surface	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
ER to Golgi transport vesicle membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
secretory granule membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
phagocytic vesicle membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
early endosome membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
recycling endosome membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
extracellular exosome	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
lumenal side of endoplasmic reticulum membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
MHC class I protein complex	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
extracellular space	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
external side of plasma membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
plasma membrane	Gamma-aminobutyric acid receptor subunit gamma-2	Rattus norvegicus (Norway rat)
plasma membrane	Glutamate receptor 2	Rattus norvegicus (Norway rat)
plasma membrane	Gamma-aminobutyric acid receptor subunit alpha-1	Rattus norvegicus (Norway rat)
plasma membrane	Guanine nucleotide-binding protein G	Homo sapiens (human)
plasma membrane	Gamma-aminobutyric acid receptor subunit beta-2	Rattus norvegicus (Norway rat)
fibrillar center	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
nucleoplasm	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
cytosol	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
nucleus	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
cytoplasm	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (84)

Assay ID	Title	Year	Journal	Article
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347425	Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347424	RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID447004	Anticonvulsant activity in CF1 albino mouse assessed as inhibition of minimal clonic seizure at 30 mg/kg, ip after 2 hrs	2009	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17	In vivo evaluation of diaminodiphenyls: anticonvulsant agents with minimal acute neurotoxicity.
AID447158	Anticonvulsant activity against kindle motor-induced seizure in rat assessed as after discharge duration at 100 mg/kg, ip after 75 mins by hippocampal kindling screen test	2009	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17	In vivo evaluation of diaminodiphenyls: anticonvulsant agents with minimal acute neurotoxicity.
AID447151	Anticonvulsant activity in CF1 albino mouse assessed as inhibition of minimal clonic seizure at 100 mg/kg, ip after 0.25 hrs	2009	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17	In vivo evaluation of diaminodiphenyls: anticonvulsant agents with minimal acute neurotoxicity.
AID446996	Anticonvulsant activity in Sprague-Dawley rat assessed as inhibition of maximal electric shock-induced seizure at 30 mg/kg, po after 0.25 hrs	2009	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17	In vivo evaluation of diaminodiphenyls: anticonvulsant agents with minimal acute neurotoxicity.
AID115844	Compound was tested for the number of control mice with decreased RBC to that of number of tested mice at 100 mg/kg p.o.; 8/8	1998	Bioorganic & medicinal chemistry letters, Jan-06, Volume: 8, Issue:1	Discovery of FR115092: a novel antinephritic agent.
AID447147	Anticonvulsant activity in CF1 albino mouse assessed as inhibition of minimal clonic seizure at 80 mg/kg, ip after 0.5 hrs	2009	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17	In vivo evaluation of diaminodiphenyls: anticonvulsant agents with minimal acute neurotoxicity.
AID447161	Anticonvulsant activity against kindle motor-induced seizure in rat assessed as after discharge duration at 100 mg/kg, ip after 165 mins by hippocampal kindling screen test	2009	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17	In vivo evaluation of diaminodiphenyls: anticonvulsant agents with minimal acute neurotoxicity.
AID446998	Anticonvulsant activity in Sprague-Dawley rat assessed as inhibition of maximal electric shock-induced seizure at 30 mg/kg, po after 1 hrs	2009	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17	In vivo evaluation of diaminodiphenyls: anticonvulsant agents with minimal acute neurotoxicity.
AID446992	Anticonvulsant activity in CF1 albino mouse assessed as inhibition of maximal electric shock-induced seizure at 300 mg/kg, ip after 0.5 hrs	2009	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17	In vivo evaluation of diaminodiphenyls: anticonvulsant agents with minimal acute neurotoxicity.
AID446997	Anticonvulsant activity in Sprague-Dawley rat assessed as inhibition of maximal electric shock-induced seizure at 30 mg/kg, po after 0.5 hrs	2009	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17	In vivo evaluation of diaminodiphenyls: anticonvulsant agents with minimal acute neurotoxicity.
AID447152	Anticonvulsant activity in CF1 albino mouse assessed as inhibition of minimal clonic seizure at 100 mg/kg, ip after 0.5 hrs	2009	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17	In vivo evaluation of diaminodiphenyls: anticonvulsant agents with minimal acute neurotoxicity.
AID447001	Anticonvulsant activity in CF1 albino mouse assessed as inhibition of minimal clonic seizure at 30 mg/kg, ip after 0.25 hrs	2009	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17	In vivo evaluation of diaminodiphenyls: anticonvulsant agents with minimal acute neurotoxicity.
AID447149	Anticonvulsant activity in CF1 albino mouse assessed as inhibition of minimal clonic seizure at 80 mg/kg, ip after 2 hrs	2009	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17	In vivo evaluation of diaminodiphenyls: anticonvulsant agents with minimal acute neurotoxicity.
AID446995	Anticonvulsant activity in CF1 albino mouse assessed as inhibition of maximal electric shock-induced seizure at 300 mg/kg, ip after 4 hrs	2009	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17	In vivo evaluation of diaminodiphenyls: anticonvulsant agents with minimal acute neurotoxicity.
AID447146	Anticonvulsant activity in CF1 albino mouse assessed as inhibition of minimal clonic seizure at 80 mg/kg, ip after 0.25 hrs	2009	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17	In vivo evaluation of diaminodiphenyls: anticonvulsant agents with minimal acute neurotoxicity.
AID446993	Anticonvulsant activity in CF1 albino mouse assessed as inhibition of maximal electric shock-induced seizure at 30 mg/kg, ip after 4 hrs	2009	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17	In vivo evaluation of diaminodiphenyls: anticonvulsant agents with minimal acute neurotoxicity.
AID447159	Anticonvulsant activity against kindle motor-induced seizure in rat assessed as after discharge duration at 100 mg/kg, ip after 105 mins by hippocampal kindling screen test	2009	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17	In vivo evaluation of diaminodiphenyls: anticonvulsant agents with minimal acute neurotoxicity.
AID447156	Anticonvulsant activity against kindle motor-induced seizure in rat assessed as after discharge duration at 100 mg/kg, ip after 15 mins by hippocampal kindling screen test	2009	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17	In vivo evaluation of diaminodiphenyls: anticonvulsant agents with minimal acute neurotoxicity.
AID446991	Anticonvulsant activity in CF1 albino mouse assessed as inhibition of maximal electric shock-induced seizure at 100 mg/kg, ip after 0.5 hrs	2009	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17	In vivo evaluation of diaminodiphenyls: anticonvulsant agents with minimal acute neurotoxicity.
AID447164	Anticonvulsant activity against kindle motor-induced seizure in rat assessed as after discharge duration at 100 mg/kg, ip after 255 mins by hippocampal kindling screen test	2009	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17	In vivo evaluation of diaminodiphenyls: anticonvulsant agents with minimal acute neurotoxicity.
AID1653410	Anti-leprotic activity against Mycobacterium leprae infected in BALB/c mouse assessed as time delay in bacterial multiplication in footpad at 0.0087 g/100g of diet administered via feed starting 60 or 75 day post infection up to 90 days by Shepard's kinet	2019	Bioorganic & medicinal chemistry, 07-01, Volume: 27, Issue:13	Insights of synthetic analogues of anti-leprosy agents.
AID446994	Anticonvulsant activity in CF1 albino mouse assessed as inhibition of maximal electric shock-induced seizure at 100 mg/kg, ip after 4 hrs	2009	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17	In vivo evaluation of diaminodiphenyls: anticonvulsant agents with minimal acute neurotoxicity.
AID447157	Anticonvulsant activity against kindle motor-induced seizure in rat assessed as after discharge duration at 100 mg/kg, ip after 45 mins by hippocampal kindling screen test	2009	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17	In vivo evaluation of diaminodiphenyls: anticonvulsant agents with minimal acute neurotoxicity.
AID117036	Inhibition of proteinuria in the graft-versus-host disease mice following 100 mg/kg p.o. administration.	1998	Bioorganic & medicinal chemistry letters, Jan-06, Volume: 8, Issue:1	Discovery of FR115092: a novel antinephritic agent.
AID447163	Anticonvulsant activity against kindle motor-induced seizure in rat assessed as after discharge duration at 100 mg/kg, ip after 225 mins by hippocampal kindling screen test	2009	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17	In vivo evaluation of diaminodiphenyls: anticonvulsant agents with minimal acute neurotoxicity.
AID447155	Anticonvulsant activity in CF1 albino mouse assessed as inhibition of minimal clonic seizure at 100 mg/kg, ip after 4 hrs	2009	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17	In vivo evaluation of diaminodiphenyls: anticonvulsant agents with minimal acute neurotoxicity.
AID447162	Anticonvulsant activity against kindle motor-induced seizure in rat assessed as after discharge duration at 100 mg/kg, ip after 195 mins by hippocampal kindling screen test	2009	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17	In vivo evaluation of diaminodiphenyls: anticonvulsant agents with minimal acute neurotoxicity.
AID447002	Anticonvulsant activity in CF1 albino mouse assessed as inhibition of minimal clonic seizure at 30 mg/kg, ip after 0.5 hrs	2009	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17	In vivo evaluation of diaminodiphenyls: anticonvulsant agents with minimal acute neurotoxicity.
AID446999	Anticonvulsant activity in Sprague-Dawley rat assessed as inhibition of maximal electric shock-induced seizure at 30 mg/kg, po after 2 hrs	2009	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17	In vivo evaluation of diaminodiphenyls: anticonvulsant agents with minimal acute neurotoxicity.
AID447153	Anticonvulsant activity in CF1 albino mouse assessed as inhibition of minimal clonic seizure at 100 mg/kg, ip after 1 hrs	2009	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17	In vivo evaluation of diaminodiphenyls: anticonvulsant agents with minimal acute neurotoxicity.
AID447154	Anticonvulsant activity in CF1 albino mouse assessed as inhibition of minimal clonic seizure at 100 mg/kg, ip after 2 hrs	2009	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17	In vivo evaluation of diaminodiphenyls: anticonvulsant agents with minimal acute neurotoxicity.
AID447003	Anticonvulsant activity in CF1 albino mouse assessed as inhibition of minimal clonic seizure at 30 mg/kg, ip after 1 hrs	2009	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17	In vivo evaluation of diaminodiphenyls: anticonvulsant agents with minimal acute neurotoxicity.
AID447148	Anticonvulsant activity in CF1 albino mouse assessed as inhibition of minimal clonic seizure at 80 mg/kg, ip after 1 hrs	2009	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17	In vivo evaluation of diaminodiphenyls: anticonvulsant agents with minimal acute neurotoxicity.
AID447160	Anticonvulsant activity against kindle motor-induced seizure in rat assessed as after discharge duration at 100 mg/kg, ip after 135 mins by hippocampal kindling screen test	2009	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17	In vivo evaluation of diaminodiphenyls: anticonvulsant agents with minimal acute neurotoxicity.
AID433903	Hepatotoxicity in mouse assessed as carcinogenic potency	2009	European journal of medicinal chemistry, Sep, Volume: 44, Issue:9	Development of QSAR models for predicting hepatocarcinogenic toxicity of chemicals.
AID447005	Anticonvulsant activity in CF1 albino mouse assessed as inhibition of minimal clonic seizure at 30 mg/kg, ip after 4 hrs	2009	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17	In vivo evaluation of diaminodiphenyls: anticonvulsant agents with minimal acute neurotoxicity.
AID447150	Anticonvulsant activity in CF1 albino mouse assessed as inhibition of minimal clonic seizure at 80 mg/kg, ip after 4 hrs	2009	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17	In vivo evaluation of diaminodiphenyls: anticonvulsant agents with minimal acute neurotoxicity.
AID447006	Neurotoxicity in CF1 albino mouse at 300 mg/kg, ip by rotarod test after 4 hrs	2009	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17	In vivo evaluation of diaminodiphenyls: anticonvulsant agents with minimal acute neurotoxicity.
AID446990	Anticonvulsant activity in CF1 albino mouse assessed as inhibition of maximal electric shock-induced seizure at 30 mg/kg, ip after 0.5 hrs	2009	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17	In vivo evaluation of diaminodiphenyls: anticonvulsant agents with minimal acute neurotoxicity.
AID447000	Anticonvulsant activity in Sprague-Dawley rat assessed as inhibition of maximal electric shock-induced seizure at 30 mg/kg, po after 4 hrs	2009	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17	In vivo evaluation of diaminodiphenyls: anticonvulsant agents with minimal acute neurotoxicity.
AID540299	A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis	2010	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21	Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519	A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities	2011	Antiviral research, Sep, Volume: 91, Issue:3	High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (25)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	1 (4.00)	18.7374
1990's	2 (8.00)	18.2507
2000's	6 (24.00)	29.6817
2010's	10 (40.00)	24.3611
2020's	6 (24.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 22.45

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	22.45 (24.57)
Research Supply Index	3.26 (2.92)
Research Growth Index	5.12 (4.65)
Search Engine Demand Index	21.17 (26.88)
Search Engine Supply Index	2.00 (0.95)

This Compound (22.45)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	1 (4.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	24 (96.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
chlordecone [no description available]	2.05	1	cyclic ketone; organochlorine compound	insecticide; persistent organic pollutant
pyrazinamide pyrazinecarboxamide : A monocarboxylic acid amide resulting from the formal condensation of the carboxy group of pyrazinoic acid (pyrazine-2-carboxylic acid) with ammonia. A prodrug for pyrazinoic acid, pyrazinecarboxamide is used as part of multidrug regimens for the treatment of tuberculosis.	3.31	1	monocarboxylic acid amide; N-acylammonia; pyrazines	antitubercular agent; prodrug
phenytoin [no description available]	2.05	1	imidazolidine-2,4-dione	anticonvulsant; drug allergen; sodium channel blocker; teratogenic agent
ciprofloxacin Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.. ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.	3.31	1	aminoquinoline; cyclopropanes; fluoroquinolone antibiotic; N-arylpiperazine; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone; zwitterion	antibacterial drug; antiinfective agent; antimicrobial agent; DNA synthesis inhibitor; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; environmental contaminant; topoisomerase IV inhibitor; xenobiotic
clofazimine Clofazimine: A fat-soluble riminophenazine dye used for the treatment of leprosy. It has been used investigationally in combination with other antimycobacterial drugs to treat Mycobacterium avium infections in AIDS patients. Clofazimine also has a marked anti-inflammatory effect and is given to control the leprosy reaction, erythema nodosum leprosum. (From AMA Drug Evaluations Annual, 1993, p1619). clofazimine : 3-Isopropylimino-3,5-dihydro-phenazine in which the hydrogen at position 5 is substituted substituted by a 4-chlorophenyl group, and that at position 2 is substituted by a (4-chlorophenyl)amino group. A dark red crystalline solid, clofazimine is an antimycobacterial and is one of the main drugs used for the treatment of multi-bacillary leprosy. However, it can cause red/brown discolouration of the skin, so other treatments are often preferred in light-skinned patients.	3.31	1	monochlorobenzenes; phenazines	dye; leprostatic drug; non-steroidal anti-inflammatory drug
dapsone [no description available]	3.55	2	substituted aniline; sulfone	anti-inflammatory drug; antiinfective agent; antimalarial; leprostatic drug
dichlorodiphenyl dichloroethylene Dichlorodiphenyl Dichloroethylene: An organochlorine pesticide, it is the ethylene metabolite of DDT.	2.05	1	chlorophenylethylene; monochlorobenzenes	human xenobiotic metabolite; persistent organic pollutant
isoniazid Hydra: A genus of freshwater polyps in the family Hydridae, order Hydroida, class HYDROZOA. They are of special interest because of their complex organization and because their adult organization corresponds roughly to the gastrula of higher animals.. hydrazide : Compounds derived from oxoacids RkE(=O)l(OH)m (l =/= 0) by replacing -OH by -NRNR2 (R groups are commonly H). (IUPAC).	3.31	1	carbohydrazide	antitubercular agent; drug allergen
ofloxacin Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.. 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.. ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.	3.31	1	3-oxo monocarboxylic acid; N-arylpiperazine; N-methylpiperazine; organofluorine compound; oxazinoquinoline
aminosalicylic acid Aminosalicylic Acid: An antitubercular agent often administered in association with ISONIAZID. The sodium salt of the drug is better tolerated than the free acid.. 4-aminosalicylic acid : An aminobenzoic acid that is salicylic acid substituted by an amino group at position 4.	3.31	1	aminobenzoic acid; phenols	antitubercular agent
4-dichlorobenzene dichlorobenzene : Any member of the class of chlorobenzenes carrying two chloro groups at unspecified positions.. 1,4-dichlorobenzene : A dichlorobenzene carrying chloro groups at positions 1 and 4.	2.05	1	dichlorobenzene	insecticide
pyrimethamine Maloprim: contains above 2 cpds	3.31	1	aminopyrimidine; monochlorobenzenes	antimalarial; antiprotozoal drug; EC 1.5.1.3 (dihydrofolate reductase) inhibitor
sulfasalazine Sulfasalazine: A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907). sulfasalazine : An azobenzene consisting of diphenyldiazene having a carboxy substituent at the 4-position, a hydroxy substituent at the 3-position and a 2-pyridylaminosulphonyl substituent at the 4'-position.	2.05	1
sulfisoxazole Sulfisoxazole: A short-acting sulfonamide antibacterial with activity against a wide range of gram- negative and gram-positive organisms.. sulfisoxazole : A sulfonamide antibacterial with an oxazole substituent. It has antibiotic activity against a wide range of gram-negative and gram-positive organisms.	2.05	1	isoxazoles; sulfonamide antibiotic; sulfonamide	antibacterial drug; drug allergen
thalidomide Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.. thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.. 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.	3.31	1	phthalimides; piperidones
trifluralin Trifluralin: A microtubule-disrupting pre-emergence herbicide.. trifluralin : A substituted aniline that is N,N-dipropylaniline substituted by a nitro groups at positions 2 and 6 and a trifluoromethyl group at position 4. It is an agrochemical used as a pre-emergence herbicide.	2.05	1	(trifluoromethyl)benzenes; C-nitro compound; substituted aniline	agrochemical; environmental contaminant; herbicide; xenobiotic
trimethoprim Trimethoprim: A pyrimidine inhibitor of dihydrofolate reductase, it is an antibacterial related to PYRIMETHAMINE. It is potentiated by SULFONAMIDES and the TRIMETHOPRIM, SULFAMETHOXAZOLE DRUG COMBINATION is the form most often used. It is sometimes used alone as an antimalarial. TRIMETHOPRIM RESISTANCE has been reported.. trimethoprim : An aminopyrimidine antibiotic whose structure consists of pyrimidine 2,4-diamine and 1,2,3-trimethoxybenzene moieties linked by a methylene bridge.	3.31	1	aminopyrimidine; methoxybenzenes	antibacterial drug; diuretic; drug allergen; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; environmental contaminant; xenobiotic
chloramphenicol Amphenicol: Chloramphenicol and its derivatives.	3.31	1	C-nitro compound; carboxamide; diol; organochlorine compound	antibacterial drug; antimicrobial agent; Escherichia coli metabolite; geroprotector; Mycoplasma genitalium metabolite; protein synthesis inhibitor
kanamycin a Kanamycin: Antibiotic complex produced by Streptomyces kanamyceticus from Japanese soil. Comprises 3 components: kanamycin A, the major component, and kanamycins B and C, the minor components.. kanamycin : Kanamycin is a naturally occurring antibiotic complex from Streptomyces kanamyceticus that consists of several components: kanamycin A, the major component (also usually designated as kanamycin), and kanamycins B, C, D and X the minor components.	3.31	1	kanamycins	bacterial metabolite
chloroform Chloroform: A commonly used laboratory solvent. It was previously used as an anesthetic, but was banned from use in the U.S. due to its suspected carcinogenicity.. chloroform : A one-carbon compound that is methane in which three of the hydrogens are replaced by chlorines.	2.05	1	chloromethanes; one-carbon compound	carcinogenic agent; central nervous system drug; inhalation anaesthetic; non-polar solvent; refrigerant
hexachloroethane [no description available]	2.05	1	chlorocarbon; chloroethanes	carcinogenic agent; refrigerant
perthane perthane: structure	2.05	1
ethyl chloride Ethyl Chloride: A gas that condenses under slight pressure. Because of its low boiling point ethyl chloride sprayed on skin produces an intense cold by evaporation. Cold blocks nerve conduction. Ethyl chloride has been used in surgery but is primarily used to relieve local pain in sports medicine.. chloroethane : The simplest and least toxic member of the class of chloroethanes, that is ethane in which a single hydrogen is substituted by a chlorine. A colourless gas at room temperature and pressure (boiling point 12degreeC), it is used as a mild topical anaesthetic to numb the skin prior to ear piercing, skin biopsies, etc., and is also used in the treatment of sports injuries. It was formerly used in the production of tetraethyllead.	2.05	1	chloroethanes	antipruritic drug; inhalation anaesthetic; local anaesthetic
methylene chloride Methylene Chloride: A chlorinated hydrocarbon that has been used as an inhalation anesthetic and acts as a narcotic in high concentrations. Its primary use is as a solvent in manufacturing and food technology.. dichloromethane : A member of the class of chloromethanes that is methane in which two of the hydrogens have been replaced by chlorine. A dense, non-flammible colourless liquid at room temperature (b.p. 40degreeC, d = 1.33) which is immiscible with water, it is widely used as a solvent, a paint stripper, and for the removal of caffeine from coffee and tea.	2.05	1	chloromethanes; volatile organic compound	carcinogenic agent; polar aprotic solvent; refrigerant
bromodichloromethane bromodichloromethane: RN given refers to parent cpd. bromodichloromethane : A halomethane that is dichloromethane in which oneof the hydrogens has been replaced by a bromine atom. It occurs as a contaminant in drinking water.	2.05	1	halomethane	environmental contaminant; reagent
pentachloroethane [no description available]	2.05	1	chloroethanes	non-polar solvent
acedapsone Acedapsone: Acetylated sulfone that is slowly metabolized to give long-term, low blood levels of DAPSONE. It has antimicrobial and antimalarial action, but is mainly used as a depot leprostatic agent.. acedapsone : A sulfone that is dapsone in which both of the amino groups been acetylation. An antimicrobial drug, it also has antimalarial activity.	3.31	1	acetamides; anilide; secondary carboxamide; sulfone	antimalarial; antimicrobial drug
1,1,2-trichloroethane 1,1,2-trichloroethane: RN given refers to cpd with locants as specified. 1,1,2-trichloroethane : A member of the class of chloroethanes that is ethane substituted by chloro groups at positions 1, 1 and 2.	2.05	1	chloroethanes
trichloroethylene Trichloroethylene: A highly volatile inhalation anesthetic used mainly in short surgical procedures where light anesthesia with good analgesia is required. It is also used as an industrial solvent. Prolonged exposure to high concentrations of the vapor can lead to cardiotoxicity and neurological impairment.. triol : A chemical compound containing three hydroxy groups.	2.05	1	chloroethenes	inhalation anaesthetic; mouse metabolite
1,1,2,2-tetrachloroethane 1,1,2,2-tetrachloroethane: see also record for tetrachloroethane. 1,1,2,2-tetrachloroethane : A member of the class of chloroethanes that is ethane substituted by chloro groups at positions 1, 1, 2 and 2.	2.05	1	chloroethanes
bis(4-hydroxyphenyl)sulfone bis(4-hydroxyphenyl)sulfone: structure and RN in first source. 4,4'-sulfonyldiphenol : A sulfone that is diphenyl sulfone in which both of the para hydrogens have been replaced by hydroxy groups.	3.31	1	bisphenol; sulfone	endocrine disruptor; metabolite
1-amino-2,4-dibromoanthraquinone 1-amino-2,4-dibromoanthraquinone: intermediate in the production of dyes	2.05	1	anthraquinone
michler's ketone [no description available]	2.05	1	benzophenones
cdec CDEC: structure	2.05	1	thiocarbonyl compound
2,4-diaminotoluene 2,4-diaminotoluene: RN given refers to unlabeled parent cpd; structure. 2,4-diaminotoluene : An aminotoluene that is para-toluidine with an additional amino group at position 2.	2.05	1	aminotoluene	metabolite
4-chloro-1,2-diaminobenzene 4-chloro-1,2-diaminobenzene: RN given refers to parent cpd	2.05	1	monochlorobenzenes
1,2,3-trichloropropane [no description available]	2.05	1	organochlorine compound
5-nitro-2-toluidine 5-nitro-2-toluidine: structure given in first source; RN given refers to parent cpd. 5-nitro-o-toluidine : A C-nitro compound in which the nitro compound is meta to the amino group and para to the methyl group of o-toluidine.	2.05	1	C-nitro compound
5-nitro-2-methoxyaniline 5-nitro-2-methoxyaniline: RN given refers to parent cpd	2.05	1	4-nitroanisoles; substituted aniline
n,n,n',n'-tetramethyl-4,4'-methylenedianiline N,N,N',N'-tetramethyl-4,4'-methylenedianiline: structure given in first source	2.02	1	diarylmethane
4,4'-diaminodiphenylmethane 4,4'-diaminodiphenylmethane: RN given refers to parent cpd; structure. 4,4'-diaminodiphenylmethane : An aromatic amine that is diphenylmethane substituted at the 4-position of each benzene ring by an amino group.	3.91	3	aromatic amine	allergen; carcinogenic agent
di-(4-aminophenyl)ether di-(4-aminophenyl)ether: structure	2.72	3	aromatic ether
1,3-butadiene buta-1,3-diene : A butadiene with unsaturation at positions 1 and 3.	2.05	1	butadiene	carcinogenic agent; mutagen
tetrahydrofuran oxolane : A cyclic ether that is butane in which one hydrogen from each methyl group is substituted by an oxygen.	2.05	1	cyclic ether; oxolanes; saturated organic heteromonocyclic parent; volatile organic compound	polar aprotic solvent
tetrafluoroethylene tetrafluoroethylene: RN given refers to parent cpd; structure	2.05	1	fluorocarbon
2-aminoanthraquinone [no description available]	2.05	1	anthraquinone
cresidine cresidine: structure	2.05	1	methoxybenzenes
amiben Amiben: RN given refers to parent cpd	2.05	1	chlorobenzoic acid
2,4,5-trimethylaniline 2,4,5-trimethylaniline: RN given refers to parent cpd	2.05	1	substituted aniline
chlorobenzilate chlorobenzilate: structure	2.05	1	diarylmethane
monoacetyldapsone monoacetyldapsone: used in leprosy chemotherapy. monoacetyldapsone : A secondary carboxamide resulting from acetylation of one of the amino groups of dapsone.	3.31	1	acetamides; anilide; secondary carboxamide; sulfone
5-nitroacenaphthene [no description available]	2.05	1	nitronaphthalene
4-methoxy-3-phenylenediamine 4-methoxy-3-phenylenediamine: RN given refers to parent cpd	2.69	3	methoxybenzenes
1,1,1,2-tetrachloroethane 1,1,1,2-tetrachloroethane: see also record for tetrachloroethane	2.05	1	chloroethanes
ethambutol Ethambutol: An antitubercular agent that inhibits the transfer of mycolic acids into the cell wall of the tubercle bacillus. It may also inhibit the synthesis of spermidine in mycobacteria. The action is usually bactericidal, and the drug can penetrate human cell membranes to exert its lethal effect. (From Smith and Reynard, Textbook of Pharmacology, 1992, p863). ethambutol : An ethylenediamine derivative that is ethane-1,2-diamine in which one hydrogen attached to each of the nitrogens is sutstituted by a 1-hydroxybutan-2-yl group (S,S-configuration). It is a bacteriostatic antimycobacterial drug, effective against Mycobacterium tuberculosis and some other mycobacteria. It is used (as the dihydrochloride salt) in combination with other antituberculous drugs in the treatment of pulmonary and extrapulmonary tuberculosis; resistant strains of M. tuberculosis are readily produced if ethambutol is used alone.	3.31	1	ethanolamines; ethylenediamine derivative	antitubercular agent; environmental contaminant; xenobiotic
2,3,7,8-tetrachlorodibenzodioxine Tetrachlorodibenzodioxin: A mixture of isomers.	2.05	1	polychlorinated dibenzodioxine
nitrofen nitrofen: structure	2.05	1	organic molecular entity	EC 1.3.3.4 (protoporphyrinogen oxidase) inhibitor; herbicide
1,5-naphthalenediamine 1,5-diaminonaphthalene: structure in first source. naphthalene-1,5-diamine : A naphthalenediamine compound having amino substituents in the 1- and 5-positions.	2.05	1	naphthalenediamine	carcinogenic agent
n-methylamino-2-nitro-4-n',n'-bis(2-hydroxyethyl)aminobenzene N-methylamino-2-nitro-4-N',N'-bis(2-hydroxyethyl)aminobenzene: structure	2.05	1	C-nitro compound
streptomycin [no description available]	3.31	1	antibiotic antifungal drug; antibiotic fungicide; streptomycins	antibacterial drug; antifungal agrochemical; antimicrobial agent; antimicrobial drug; bacterial metabolite; protein synthesis inhibitor
1,2-diphenylhydrazine [no description available]	2.05	1
1,4-dioxane 1,4-dioxane: dehydrating agent; polar solvent miscible both with water & most organic solvents. dioxane : Any member of the class of dioxanes that is a cyclohexane in which two carbon atoms are replaced by oxygen atoms.. 1,4-dioxane : A dioxane with oxygen atoms at positions 1 and 4.	2.05	1	dioxane; volatile organic compound	carcinogenic agent; metabolite; NMR chemical shift reference compound; non-polar solvent
chloroprene Chloroprene: Toxic, possibly carcinogenic, monomer of neoprene, a synthetic rubber; causes damage to skin, lungs, CNS, kidneys, liver, blood cells and fetuses. Synonym: 2-chlorobutadiene.	2.05	1	chloroolefin
tetrachloroethylene Tetrachloroethylene: A chlorinated hydrocarbon used as an industrial solvent and cooling liquid in electrical transformers. It is a potential carcinogen.	2.05	1	chlorocarbon; chloroethenes	nephrotoxic agent
tobramycin Tobramycin: An aminoglycoside, broad-spectrum antibiotic produced by Streptomyces tenebrarius. It is effective against gram-negative bacteria, especially the PSEUDOMONAS species. It is a 10% component of the antibiotic complex, NEBRAMYCIN, produced by the same species.. tobramycin : A amino cyclitol glycoside that is kanamycin B lacking the 3-hydroxy substituent from the 2,6-diaminoglucose ring.	3.31	1	amino cyclitol glycoside	antibacterial agent; antimicrobial agent; toxin
amikacin Amikacin: A broad-spectrum antibiotic derived from KANAMYCIN. It is reno- and oto-toxic like the other aminoglycoside antibiotics.. amikacin : An amino cyclitol glycoside that is kanamycin A acylated at the N-1 position by a 4-amino-2-hydroxybutyryl group.	3.31	1	alpha-D-glucoside; amino cyclitol glycoside; aminoglycoside; carboxamide	antibacterial drug; antimicrobial agent; nephrotoxin
4-amino-4'-hydroxylaminodiphenylsulfone 4-amino-4'-hydroxylaminodiphenylsulfone: RN given refers to unlabeled cpd	3.31	1	sulfonic acid derivative
acediasulfone acediasulfone: antibacterial drug for treatment of ear infections; structure in first source	3.31	1	alpha-amino acid
brodimoprim brodimoprim: inhibits dihydrofolate reductase. brodimoprim : An aminopyrimidine that is 2,4-diaminopyrimidine in which the hydrogen at position 5 has been replaced by a 4-bromo-3,5-dimethoxybenzyl group.	3.31	1	aminopyrimidine; bromobenzenes; methoxybenzenes	antibacterial drug; antiinfective agent; EC 1.5.1.3 (dihydrofolate reductase) inhibitor
epiroprim epiroprim: an analog of trimethoprim with improved antimicrobial and pharmacokinetic properties; structure given in first source	3.31	1
4,4'-diaminobenzophenone 4,4'-diaminobenzophenone: structure in first source	2.42	2
4,4'-diaminobenzanilide 4,4'-diaminobenzanilide: not carcinogenic	2.42	2
gentamicin c1a [no description available]	3.31	1	gentamycin C
4-nitro-4'-aminodiphenyl sulfone 4-nitro-4'-aminodiphenyl sulfone: dapsone metabolite; structure given in first source	3.31	1
imipenem, anhydrous Imipenem: Semisynthetic thienamycin that has a wide spectrum of antibacterial activity against gram-negative and gram-positive aerobic and anaerobic bacteria, including many multiresistant strains. It is stable to beta-lactamases. Clinical studies have demonstrated high efficacy in the treatment of infections of various body systems. Its effectiveness is enhanced when it is administered in combination with CILASTATIN, a renal dipeptidase inhibitor.. imipenem : A broad-spectrum, intravenous beta-lactam antibiotic of the carbapenem subgroup.	3.31	1	beta-lactam antibiotic allergen; carbapenems; zwitterion	antibacterial drug
methotrexate [no description available]	3.31	1	dicarboxylic acid; monocarboxylic acid amide; pteridines	abortifacient; antimetabolite; antineoplastic agent; antirheumatic drug; dermatologic drug; DNA synthesis inhibitor; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; immunosuppressive agent
levofloxacin Levofloxacin: The L-isomer of Ofloxacin.. levofloxacin : An optically active form of ofloxacin having (S)-configuration; an inhibitor of bacterial topoisomerase IV and DNA gyrase.	3.31	1	9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid; fluoroquinolone antibiotic; quinolone antibiotic	antibacterial drug; DNA synthesis inhibitor; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; topoisomerase IV inhibitor
aminopterin Aminopterin: A folic acid derivative used as a rodenticide that has been shown to be teratogenic.	3.31	1	dicarboxylic acid	EC 1.5.1.3 (dihydrofolate reductase) inhibitor; mutagen
(+)-limonene (4R)-limonene : An optically active form of limonene having (4R)-configuration.	2.05	1	limonene	plant metabolite
sitafloxacin [no description available]	3.31	1	fluoroquinolone antibiotic; quinolines; quinolone antibiotic
9-benzyl-2-chloro-6-(2-furyl)purine 9-benzyl-2-chloro-6-(2-furyl)purine: structure in first source	3.31	1
propylthiouracil Propylthiouracil: A thiourea antithyroid agent. Propythiouracil inhibits the synthesis of thyroxine and inhibits the peripheral conversion of throxine to tri-iodothyronine. It is used in the treatment of hyperthyroidism. (From Martindale, The Extra Pharmacopeoia, 30th ed, p534). 6-propyl-2-thiouracil : A pyrimidinethione consisting of uracil in which the 2-oxo group is substituted by a thio group and the hydrogen at position 6 is substituted by a propyl group.	2.02	1	pyrimidinethione	antidote to paracetamol poisoning; antimetabolite; antioxidant; antithyroid drug; carcinogenic agent; EC 1.14.13.39 (nitric oxide synthase) inhibitor; hormone antagonist
ethylenethiourea Ethylenethiourea: A degradation product of ethylenebis(dithiocarbamate) fungicides. It has been found to be carcinogenic and to cause THYROID hyperplasia.	2.05	1	imidazolidines
thiourea Thiourea: A photographic fixative used also in the manufacture of resins. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance may reasonably be anticipated to be a carcinogen (Merck Index, 9th ed). Many of its derivatives are ANTITHYROID AGENTS and/or FREE RADICAL SCAVENGERS.. thiourea : The simplest member of the thiourea class, consisting of urea with the oxygen atom substituted by sulfur.	2.39	2	one-carbon compound; thioureas; ureas	antioxidant; chromophore
ethionamide Ethionamide: A second-line antitubercular agent that inhibits mycolic acid synthesis.. ethionamide : A thiocarboxamide that is pyridine-4-carbothioamide substituted by an ethyl group at position 2. A prodrug that undergoes metabolic activation by conversion to the corresponding S-oxide.	3.31	1	pyridines; thiocarboxamide	antilipemic drug; antitubercular agent; fatty acid synthesis inhibitor; leprostatic drug; prodrug
cerulenin Cerulenin: An epoxydodecadienamide isolated from several species, including ACREMONIUM, Acrocylindrum, and Helicoceras. It inhibits the biosynthesis of several lipids by interfering with enzyme function.. cerulenin : An epoxydodecadienamide isolated from several species, including Acremonium, Acrocylindrum and Helicoceras. It inhibits the biosynthesis of several lipids by interfering with enzyme function.	3.31	1	epoxide; monocarboxylic acid amide	antifungal agent; antiinfective agent; antilipemic drug; antimetabolite; antimicrobial agent; fatty acid synthesis inhibitor
cinnamyl anthranilate [no description available]	2.05	1	benzoate ester
rifampin Rifampin: A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)	3.31	1	cyclic ketal; hydrazone; N-iminopiperazine; N-methylpiperazine; rifamycins; semisynthetic derivative; zwitterion	angiogenesis inhibitor; antiamoebic agent; antineoplastic agent; antitubercular agent; DNA synthesis inhibitor; EC 2.7.7.6 (RNA polymerase) inhibitor; Escherichia coli metabolite; geroprotector; leprostatic drug; neuroprotective agent; pregnane X receptor agonist; protein synthesis inhibitor
thiolactomycin thiolactomycin: from actinomycetes; structure given in first source	3.31	1
rifabutin [no description available]	3.31	1
3'-hydroxy-5'-(4-isobutylpiperazinyl)benzoxazinorifamycin KRM 1648: structure in first source	3.31	1	phenoxazine
krm 1657 KRM 1657: structure given in first source	3.31	1

Condition	Relationship Strength	Studies
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2.74	3
Nephritis Inflammation of any part of the KIDNEY.	1.99	1
Anemia A reduction in the number of circulating ERYTHROCYTES or in the quantity of HEMOGLOBIN.	1.99	1
Absence Seizure [description not available]	2.05	1
Seizures Clinical or subclinical disturbances of cortical function due to a sudden, abnormal, excessive, and disorganized discharge of brain cells. Clinical manifestations include abnormal motor, sensory and psychic phenomena. Recurrent seizures are usually referred to as EPILEPSY or seizure disorder.	2.05	1
Innate Inflammatory Response [description not available]	2.05	1
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	2.05	1
Encephalitis, Polio [description not available]	2.06	1
Poliomyelitis An acute infectious disease of humans, particularly children, caused by any of three serotypes of human poliovirus (POLIOVIRUS). Usually the infection is limited to the gastrointestinal tract and nasopharynx, and is often asymptomatic. The central nervous system, primarily the spinal cord, may be affected, leading to rapidly progressive paralysis, coarse FASCICULATION and hyporeflexia. Motor neurons are primarily affected. Encephalitis may also occur. The virus replicates in the nervous system, and may cause significant neuronal loss, most notably in the spinal cord. A rare related condition, nonpoliovirus poliomyelitis, may result from infections with nonpoliovirus enteroviruses. (From Adams et al., Principles of Neurology, 6th ed, pp764-5)	2.06	1
Hansen Disease [description not available]	3.12	1
Leprosy A chronic granulomatous infection caused by MYCOBACTERIUM LEPRAE. The granulomatous lesions are manifested in the skin, the mucous membranes, and the peripheral nerves. Two polar or principal types are lepromatous and tuberculoid.	3.12	1
Congenital Zika Syndrome [description not available]	2.25	1
Zika Virus Infection A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, in rare cases, is associated with congenital brain and ocular abnormalities, called Congenital Zika Syndrome, including MICROCEPHALY and may also lead to GUILLAIN-BARRE SYNDROME.	2.25	1
Benign Neoplasms [description not available]	2.06	1
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	2.06	1
Adenoma, Hepatocellular [description not available]	2.01	1
Carcinoma, Papillary A malignant neoplasm characterized by the formation of numerous, irregular, finger-like projections of fibrous stroma that is covered with a surface layer of neoplastic epithelial cells. (Stedman, 25th ed)	2.01	1
Cancer of Liver [description not available]	2.01	1
Cancer of Lung [description not available]	2.01	1
Experimental Neoplasms [description not available]	2.38	2
Cancer of the Thyroid [description not available]	2.39	2
Hyperplasia An increase in the number of cells in a tissue or organ without tumor formation. It differs from HYPERTROPHY, which is an increase in bulk without an increase in the number of cells.	2.01	1
Liver Neoplasms Tumors or cancer of the LIVER.	2.01	1
Lung Neoplasms Tumors or cancer of the LUNG.	2.01	1
Thyroid Neoplasms Tumors or cancer of the THYROID GLAND.	2.39	2
Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.	1.96	1

chemdatabank.com